EcoDrugPlus

Bradykinin Receptor B1

Ensembl ID : ENSOKIG00005019796
Gene Symbol: BDKRB1
1 Cross references
141 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSOKIG00005032988
Gene Symbol: BDKRB2
1 Cross references
148 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSOKIG00005019768
Gene Symbol: BDKRB2
1 Cross references
277 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSOKIG00005013844
Gene Symbol: BDKRB2
3 Cross references
149 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSOKIG00005024691
Gene Symbol: BDKRB2
3 Cross references
282 Possible Orthologues:

Breakpoint Cluster Region Protein

Ensembl ID : ENSOKIG00005041470
Gene Symbol: LOC109895778
3 Cross references
190 Possible Orthologues:

Breakpoint Cluster Region Protein-Like

Ensembl ID : ENSOKIG00005042578
Gene Symbol: LOC109878205
3 Cross references
190 Possible Orthologues:

Cgmp-Specific 3',5'-Cyclic Phosphodiesterase

Ensembl ID : ENSOKIG00005040433
Gene Symbol: LOC109906607
3 Cross references
217 Possible Orthologues:

Cgmp-Specific 3',5'-Cyclic Phosphodiesterase-Like

Ensembl ID : ENSOKIG00005024427
Gene Symbol: LOC109896475
3 Cross references
217 Possible Orthologues:

Calcitonin Receptor Like Receptor

Ensembl ID : ENSOKIG00005027065
Gene Symbol: CALCRL
3 Cross references
141 Possible Orthologues:

Calcitonin Receptor Like Receptor

Ensembl ID : ENSOKIG00005018659
Gene Symbol: CALCRL
3 Cross references
141 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSOKIG00005041676
Gene Symbol: CACNA1C
1 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).